Valeant selling 4 assets for $2.1B in cash grab: 4 takeaways
To combat its $30 billion debt, Lovell, Canada-based Valeant Pharmaceuticals is selling its Dendreon cancer business and three of its skincare brands for $2.12 billion.
Here's what you should know.
1. Valeant is selling its Dendreon immunotherapy prostate cancer business to China-based Sanpower Group for $819.9 million.
2. Additionally, Valeant is selling its CeraVe, AMBI Skincare and AcneFree skincare brands to Île-de-France-based L'Oreal for $1.3 billion.
The three product lines yielded an annual revenue of $168 million for Valeant.
3. Valeant expects to close on both transactions in early 2017.
4. The sales' proceeds will pay back some of Valeant's term loan debt.
More articles on gastroenterology/endoscopy:
GI leader to know: Dr. Bitman Stewart of Digestive Care
Integrated Endoscopy seeks $4.4M for executive compensation: 3 key notes
Hallmark Health Medical Associates names gastroenterologist Dr. Michael Newman president: 3 key notes
© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
- CareCloud launches guarantee to help providers avoid MIPS penalties
- Blue Cross Blue Shield of Georgia appoints pain physician as CMO: 5 key notes
- Moving onto the next 100 TJRs: How this Ohio ASC's TJR program continues to evolve
- Allergan CEO faces 80.8% pay cut & more — 3 GI companies making waves
- Rules I follow to always get my man (and woman)